ONC Stock Overview
A precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
My Notes
Capture your thoughts, links and company narrative
Oncimmune Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.15 |
| 52 Week High | UK£0.31 |
| 52 Week Low | UK£0.093 |
| Beta | 1.33 |
| 1 Month Change | -1.66% |
| 3 Month Change | -14.94% |
| 1 Year Change | -42.41% |
| 3 Year Change | -91.29% |
| 5 Year Change | -61.56% |
| Change since IPO | -88.83% |
Recent News & Updates
Shareholder Returns
| ONC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -5.4% | -3.2% | -1.5% |
| 1Y | -42.4% | -21.4% | 3.5% |
Return vs Industry: ONC underperformed the UK Biotechs industry which returned -21.4% over the past year.
Return vs Market: ONC underperformed the UK Market which returned 3.5% over the past year.
Price Volatility
| ONC volatility | |
|---|---|
| ONC Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ONC's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: ONC's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 38 | Martin Gouldstone | www.oncimmune.com |
Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. It offers ImmunoINSIGHTS, an autoantibody profiling service that unlocks the immune system to discover and convert autoantibodies into actionable biomarkers; Sero Tag, a discovery engine which identifies relevant biomarker pool for target discovery or companion diagnostics; NavigAID, a creation of a disease-specific biomarker panel; and Autoantibody Biomarkers, a companion diagnostic biomarker. The company also provides business development and marketing services.
Oncimmune Holdings plc Fundamentals Summary
| ONC fundamental statistics | |
|---|---|
| Market cap | UK£16.54m |
| Earnings (TTM) | -UK£3.14m |
| Revenue (TTM) | UK£1.21m |
13.6x
P/S Ratio-5.3x
P/E RatioIs ONC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONC income statement (TTM) | |
|---|---|
| Revenue | UK£1.21m |
| Cost of Revenue | UK£445.00k |
| Gross Profit | UK£769.00k |
| Other Expenses | UK£3.91m |
| Earnings | -UK£3.14m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 63.34% |
| Net Profit Margin | -258.65% |
| Debt/Equity Ratio | -404.9% |
How did ONC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 22:05 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/02/29 |
| Annual Earnings | 2023/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oncimmune Holdings plc is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Bardo | Berenberg |
| Stuart Harris | Cavendish |
| Emma Ulker | Zeus Capital Limited |